Genelux Corporation (GNLX)
| Previous Close | 2.2200 |
| Open | 2.3300 |
| Bid | 1.6800 x 200 |
| Ask | 2.6100 x 200 |
| Day's Range | 2.0400 - 2.2501 |
| 52 Week Range | 1.6000 - 28.3600 |
| Volume | |
| Avg. Volume | 212,880 |
| Market Cap | 73.585M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9500 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.20 |
GlobeNewswireGenelux Corporation to Present at the H.C. Wainwright Global Investment Conference
WESTLAKE VILLAGE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, Chairman and CEO, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at the H.C. Wainwright Global Healthcare Conference, taking place September 9-11, 2024, in New York City, New York. The conversation with Emily Bodnar, Vice President, Equity Research an
Simply Wall St.Is Genelux (NASDAQ:GNLX) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- GlobeNewswire
Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates
WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2024 and provided general business updates. “The past quarter has continued to be transformative for the company as we completed a key financing expected to provide runway through three trial readouts, including our ongoing Phase 3 trial in platinum resistant/refractory ovarian cancer,” said Thom
